Comparison of Propofol and Midazolam for Sedation in Intensive Care Unit

Muhammad Ammar Amjad; Abdullah .; Muhammad Saeed; Syed  Majid Waseem; Muhammad Ali Abbas; Muhammad Ali

doi:10.51253/pafmj.v75i6.11169

Authors

Muhammad Ammar Amjad Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Abdullah . Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Muhammad Saeed Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Syed Majid Waseem Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Muhammad Ali Abbas Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan
Muhammad Ali Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i6.11169

Keywords:

ICU, Sedation, Propofol, Midazolam, RASS, Anxiety

Abstract

Objective: To compare the relative efficacy and extubation time by using Propofol and Midazolam for patients requiring sedation in intensive care unit.

Study Design: Quasi experimental study.

Place and Duration of Study: Intensive Care Unit, Department of Anesthesia, Combined Military Hospital Multan, Pakistan from Jan to Jul 2023.

Methodology: Sixty-two (n=62) patients fulfilling the inclusion criteria were incorporated in the study, the were divided in two group of 31 each. Group-P was infused Propofol at the dosage of 0.05mg/kg/min whereas Group-M received Midazolam as 0.1mg/kg/hour. Standard monitoring was used in both groups. End points included efficacy of sedation (RASS +1 to -2), time taken for extubation after stoppage of sedative drugs.

Results: Patients in both the groups were comparable in terms of mean age in years 45.17±14.42 and 44.40±13.56 with p value 0.83. Mean time in minutes taken for extubation was 80.40±21.35 and 92.23±22.61 (p-0.042) for Propofol and Midazolam group respectively. Richmond agitation sedation score (RASS) scores of 90% (n=27 patients) and 73.3% (n=22 patients) of the patients remained in desired limits in Propofol and Midazolam groups respectively.

Conclusion: Propofol and Midazolam demonstrated efficacy in sedating ICU patients and different profiles regarding safety. The choice of sedative to be individualized, considering the patient's clinical status and the desired sedation goals.

Downloads

Download data is not yet available.

Author Biography

Muhammad Ammar Amjad, Department of Anesthesia, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan

.

References

1. Temesgen N, Chekol B, Tamirie T, Eshetie D, Simeneh N, Feleke A. Adult sedation and analgesia in a resource limited intensive care unit–A Systematic Review and evidence based guideline. Ann Med Surg 2021; 66(6): e102356.

https://doi.org/10.1016/j.amsu.2021.102356

2. Pun BT, Badenes R, La Calle GH, Orun OM, Chen W, Raman R, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med 2021; 9(3): 239-250.

https://doi.org/10.1016/s2213-2600(20)30552-x

3. Tanaka LM, Azevedo LC, Park M, Schettino G, Nassar AP, Réa-Neto A, et al. Early sedation and clinical outcomes of mechanically ventilated patients: a prospective multicenter cohort study. J Crit care 2014; 18(4): 1-10.

https://doi.org/10.1186/cc13995

4. Shehabi Y, Bellomo R, Kadiman S, Ti LK, Howe B, Reade MC, et al. Sedation intensity in the first 48 hours of mechanical ventilation and 180-day mortality: a multinational prospective longitudinal cohort study. Crit Care Med 2018; 46(6): 850-859.

https://doi.org/10.1097/ccm.0000000000003071

5. Veiga VC, Rojas SS. Analgosedation and delirium in intensive care units in Brazil: current status. ASDUTI study. Rev Bras Ter Intensiva 2018; 30(2): 246-248.

https://doi.org/10.5935/0103-507X.20220020-pt

6. Scherer C, Kleeberger J, Kellnar A, Binzenhöfer L, Lüsebrink E, Stocker TJ, et al. Propofol versus midazolam sedation in patients with cardiogenic shock-an observational propensity-matched study. J Crit Care 2022; 71(10): e154051.

https://doi.org/10.1016/j.jcrc.2022.154051

7. Kim HH, Choi SC, Ahn JH, Chae MK, Heo J, Min YG et al. Analysis of trends in usage of analgesics and sedatives in intensive care units of South Korea: A retrospective nationwide population-based study. Medicine 2018; 97(35): e12126.

https://doi.org/10.1097/md.0000000000012126

8. Rai SA, Khan MI, Malak AM, Asghar MT. Propofol or Midazolam for Sedation and Early Extubation Following Coronary Artery Bypass Graft Surgery. Pak J Med Health Sci 2022; 16(08): 237-239.

https://doi.org/10.53350/pjmhs22168237

9. Berg KM, Soar J, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, et al. Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 2020; 142(16): 92-139.

https://doi.org/10.1161/CIR.0000000000000893

10. Sahinovic MM, Struys MM, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin pharmacokinetic 2018; 57(12): 1539-1558.

https://doi.org/10.1007/s40262-018-0672-3

11. Hanidziar D, Bittner EA. Sedation of mechanically ventilated COVID-19 patients: challenges and special considerations. Anesth Analg 2020; 131(1): 40-41.

https://doi.org/10.1213/ane.0000000000004887

12. Li WK, Chen XJ, Altshuler D, Islam S, Spiegler P, Emerson L, et al. The incidence of propofol infusion syndrome in critically-ill patients. J Crit Care 2022; 71(5): e154098.

https://doi.org/10.1016/j.jcrc.2022.154098

13. Rump K, Holtkamp C, Bergmann L, Nowak H, Unterberg M, Orlowski J, et al. Midazolam impacts acetyl and butyrylcholinesterase genes: An epigenetic explanation for postoperative delirium. Plos one 2022; 17(7): e0271119.

https://doi.org/10.1371/journal.pone.0271119

14. Opdenakker O, Vanstraelen A, De Sloovere V, Meyfroidt G. Sedatives in neurocritical care: an update on pharmacological agents and modes of sedation. Curr Opin Crit Care 2019; 25(2): 97-104.

https://doi.org/10.1097/mcc.0000000000000592

15. Hu AM, Zhong XX, Li Z, Zhang ZJ, Li HP. Comparative effectiveness of midazolam, propofol, and Dexmedetomidine in patients with or at risk for acute respiratory distress syndrome: a propensity score-matched cohort study. Front Pharmacol 2021; 12(2): e614465.

https://doi.org/10.3389/fphar.2021.614465

16. Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, et al. Dexmedetomidine or propofol for sedation in mechanically ventilated adults with sepsis. N Eng J Med 2021; 384(15): 1424-1436.

https://doi.org/10.1056/nejmoa2024922

17. Jiang X, Yan M. Comparing the impact on the prognosis of acute myocardial infarction critical patients of using midazolam, propofol, and dexmedetomidine for sedation. BMC Cardiovasc Disord 2021; 21(6): 1-8.

https://doi.org/10.1186/s12872-021-02385-9

18. Sun W, Yan Y, Hu S, Liu B, Wang S, Yu W, et al. The effects of midazolam or propofol plus fentanyl on ICU mortality: a retrospective study based on the MIMIC-IV database. Ann Transl Med 2022; 10(4): 219-226.

https://doi.org/10.21037/atm-22-477

19. Gu JW, Yang T, Kuang YQ, Huang HD, Kong B, Shu HF, et al. Comparison of the safety and efficacy of propofol with midazolam for sedation of patients with severe traumatic brain injury: a meta-analysis. J Crit Care 2014; 29(2): 287-290.

https://doi.org/10.1016/j.jcrc.2013.10.021

20. Zhou Y, Jin X, Kang Y, Liang G, Liu T, Deng N. Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study. Crit Care 2014; 18(6): 1-9.

https://doi.org/10.1186/cc13922